Navigation Links
DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of Programs
Date:11/4/2013

, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER®, ORADUR®, TRANSDUR® and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR, TRANSDUR-Sufentanil, ORADUR-Methylphenidate and Relday are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statements The statements in this press release regarding the potential FDA approval or other response to our NDA for POSIDUR, additional clinical trials and potential regulatory submissions for REMOXY, the potential benefits and uses of our drug candidates, clinical trials and product development plans by our collaborators, potential collaborations with third parties and potential business development activities are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including requests for additional information or product non-approval of our POSIDUR or other NDA submissions, the risk that Pfizer will discontinue development of REMOXY, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, our potential fai
'/>"/>

SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference Call
2. DURECT Announces Changes to its Board of Directors
3. DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
4. DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
5. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
6. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
7. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
8. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
9. DURECT to Participate in Upcoming Healthcare Conferences
10. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
11. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015  Flow cytometry remains ... the globe and keeping track of wide-ranging consumer ... market. In particular, ensuring user-friendliness, fluorescence capabilities, specialized ... the most important factors influencing end-user purchase decisions ... New analysis from Frost & Sullivan, ...
(Date:6/3/2015)... 3, 2015  VA North Texas Health Care ... of vBloc, a technology-based, scientifically advanced weight loss ... implant called the Maestro® Rechargeable System that intermittently ... messages involving food intake and processing between the ... and customizable to meet the needs of a ...
(Date:6/3/2015)... June 3, 2015  SurgiQuest®, Inc. ("SurgiQuest", the ... for minimally invasive surgery (MIS) announced today that ... over 250,000 procedures.  Adoption has risen rapidly with ... year, driven by the company,s expansion from robotics ... geographic expansion to over 45 countries.   ...
Breaking Medicine Technology:Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 2Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 3Florescent Capabilities are the Primary Focus for Laboratories with Flow Cytometer Technologies 4VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 2VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 3Rapid Procedure Growth With SurgiQuest's AirSeal System 2
... Incorporated (Nasdaq: ARAY ), a global ... Senior Vice President, General Counsel and Corporate Secretary, Darren ... by the Silicon Valley/San Jose Business Journal and ... their ,Best Bay Area Corporate Counsel Awards,. This annual awards ...
... 25, 2011 Landauer, Inc. (NYSE: LDR ... quarterly cash dividend of $0.55 per share for the second quarter ... 2011, to shareholders of record on March 11, 2011. ... provider of technical and analytical services to determine occupational and environmental ...
Cached Medicine Technology:Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 2Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 3Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 4
(Date:6/3/2015)... 03, 2015 Follow us on ... has revolutionized disease treatment on account of their better ... diseases, such as rheumatoid arthritis. The industry is expected ... traditional small molecule drugs to biopharmaceuticals over the coming ... cell and gene therapies, and recombinant proteins has attracted ...
(Date:6/3/2015)... On June 22, 2015, Medicare will ... sensitivity (pharmacogenetic) testing that it has reimbursed since 2009. ... 19 million of the 49 million Medicare beneficiaries in the ... adverse drug events.(1) Sadly, if it became a standard of ... the use of an individual’s genetic information to tailor treatment, ...
(Date:6/3/2015)... On the heels of a report predicting bioinformatics ... click here to review news coverage about the report ... has the talent to become a world-leading center of the ... biological data are collected and analyzed to help scientists discover ... elements of a perfect storm for bioinformatics leadership,” said Dr. ...
(Date:6/3/2015)... BC (PRWEB) June 03, 2015 Vancouver ... announced that the firm will now handle personal injury ... Greater Vancouver on the rise, more and more people ... year bus accidents cause needless suffering, serious injury and ... a result of a bus accident in BC you ...
(Date:6/3/2015)... NY (PRWEB) June 03, 2015 Dr. Steven ... York Cardiac Diagnostic Center ( http://www.newyorkcardiac.com ) located in NYC, ... on weekdays to his practice. In most cases, depending on ... of the day they call, they will be seen by ... first priority as a cardiologist is to ensure that people ...
Breaking Medicine News(10 mins):Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2
... study published in the Lancet, researchers had suggested that ... HPV virus might vary from country to country all ... developed against two types of virus that cause cervical ... high-risk HPV infections in Europe than sub-Saharan Africa. ...
... with the new biologic drug adalimumab and methotrexate has ... for people with long-standing rheumatoid arthritis when compared to ... been found to decrease pain and swelling in patients ... ,At the end of the 6-month trial, 43 percent ...
... could be happier than the poor taking into consideration factors ... ,The study was conducted on a group of people ... were questioned regarding their age, total family income and general ... older, race and marital status. ,The analysis of ...
... the state administration of Maharastra who have been under ... floods are now under defensive and are controlling the ... health authorities have reported fewer admissions of new ... such as leptospirosis and dengue showed signs of abating. ...
... men with early stage prostate cancer who make drastic changes ... reverse the progression of their illness say researchers//. The study ... that lifestyle changes may affect the progression of a cancer. ... in men after lung cancer. For the study researchers recruited ...
... latest BMJ said that results of a randomized controlled ... help pregnant smokers quit or cut down had yielded ... mothers//. ,A third of pregnant women smoke and ... support to help them quit. Motivational interviewing - a ...
Cached Medicine News:Health News:Trained Counselors Counseling Pregnant Smokers To Quit May Not Work 2
... The Smith & Nephew ECTRA II ... release the carpal tunnel ligament endoscopically, allowing ... proximal cutting, while minimizing endoscopic lens fogging ... the surgeon complete visualization and control. ECTRA ...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
... Cross-Screw System offers the surgeon ... for ACL reconstruction utilizing soft ... System provides the latest technology ... comes in Titanium as well ...
Medicine Products: